AlloFuse® Cortical Fibers and AlloFuse® Fiber Boat will expand the company’s osteobiologic bone graft portfolio

Centennial, Colo. — June 13, 2016 — AlloSource, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced the launch of two new innovative demineralized cortical fiber allografts, AlloFuse® Cortical Fibers and the AlloFuse® Fiber Boat, for use in a variety of spine and orthopedic procedures. TheraCell, a regenerative medicine company, developed and patented the demineralized bone fiber (DBF™) technology used in these products and partnered with AlloSource to implement manufacturing and establish a distribution network for the tissue.

“The fiber technology incorporated in these allografts offers surgeons new options for their patients,” said Thomas Cycyota, AlloSource president and CEO. “Our partnership with TheraCell allows us to maximize the gift of tissue donation, while also providing innovative products to fulfill an unmet need for healthcare professionals and recipients.”

AlloFuse Cortical Fibers and the AlloFuse Fiber Boat represent the latest additions to the AlloFuse line of osteobiologic bone grafts, originally launched in 2009. These new DBF allografts consist of 100 percent demineralized cortical bone and offer a less costly alternative to synthetic bone void fillers. The size and geometry of the fibers have been optimized to provide exceptional handling characteristics for bone fusion procedures, primarily in spine and orthopedics.

“Collaborating with AlloSource provides a great opportunity for our DBF technology to help change lives,” said Bradley Patt, Ph.D., TheraCell chairman and CEO. “We are honored to work with one of the country’s leading tissue banks to advance the science of allografts.”